blood-brain barrier

Before glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1 can be recommended for identifying cerebral lesions in mild traumatic brain injury, all influencing factors must be taken into account

Background on Biomarkers Biomarkers serve as vital indicators of biological processes, pathogenic processes, or pharmacologic responses to therapeutic interventions. In

Before glial fibrillary acidic protein and ubiquitin C-terminal hydrolase L1 can be recommended for identifying cerebral lesions in mild traumatic brain injury, all influencing factors must be taken into account Read Post »

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model

Natalizumab and Tyruko in Multiple Sclerosis Therapy Natalizumab is a monoclonal antibody that targets the alpha-4 integrin subunit, inhibiting the

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model Read Post »

Scroll to Top